Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

Abstract In 1996 and 2011, the American Society of Hematology (ASH) supported efforts to
create guidelines for the diagnosis and management of patients with immune …

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in
clinical practice. The International Working Group (IWG) on ITP has published several …

Background: Despite an increase in the number of therapies available to treat patients with
immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist …

Immune thrombocytopenia, or ITP, has been recognized as a clinical entity for centuries, and
the importance of humoral mechanisms in the pathophysiology of ITP has been recognized …

Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from
antibody-mediated destruction of platelets and impaired megakaryocyte platelet production …

Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …

Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …